What is the price target for IOBT stock?
8 analysts have analysed IOBT and the average price target is 4.08 USD. This implies a price increase of 8400% is expected in the next year compared to the current price of 0.048.
IO BIOTECH INC (IOBT) Forecast, Price Target & Analyst Ratings
NASDAQ:IOBT • US4497781090
Current stock price
0.048 USD
+0.02 (+48.61%)
At close:
0.0546 USD
+0.01 (+13.75%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IO BIOTECH INC (IOBT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
+ 8,400.00%
From current price of $0.05 to mean target of $4.08, Based on 8 analyst forecasts
Low
$4.04
Median
$4.08
High
$4.20
Price Target Revisions
1 Month
0.00%
3 Months
-69.21%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for IOBT. The average price target is 4.08 USD. This implies a price increase of 8400% is expected in the next year compared to the current price of 0.048.
The average price target has been revised downward by 69.21% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
50.00%
IOBT was analyzed by 8 analysts. The buy percentage consensus is at 50. So analysts seem to be rather neutral about IOBT.
In the previous month the buy percentage consensus was at a similar level.
IOBT was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-26 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-10-22 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-09-30 | TD Cowen | Downgrade | Buy -> Hold |
| 2025-09-29 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-08-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-09-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-28 | Piper Sandler | Initiate | Overweight |
| 2023-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-15 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Overweight |
| 2022-11-21 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-30 | Cowen & Co. | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 44.75%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
47.02%
Next Earnings Summary
IOBT is expected to report earnings on 5/1/2026. The consensus EPS estimate for the next earnings is -0.27 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A -53.29% | N/A 11.99% | N/A 57.14% | N/A 40.69% | N/A 30.77% | N/A 24.71% | ||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -71.32M -33.45% | -91.228M -27.91% | N/A -3.13% | N/A 19.58% | N/A 9.19% | N/A 46.05% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -9.91M | -10.15M -2.42% | -41.23M -306.21% | -71.42M -73.22% | -91.443M -28.04% | N/A -5.50% | N/A 16.10% | N/A 28.69% | N/A 26.12% | N/A -96.29% | N/A 78.02% | N/A 37.97% | N/A 68.37% | N/A 226.03% | N/A 201.76% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.50 46.25% | -2.16 13.60% | -1.45 32.87% | N/A 8.55% | N/A 63.46% | N/A 21.05% | N/A 54.67% | N/A 70.59% | N/A -20.00% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.27 44.75% | -0.10 70.00% | -0.08 78.14% | -0.05 64.69% | -0.03 88.46% | -0.01 90.00% | -0.01 86.67% | -0.01 77.78% | -0.01 66.67% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -17.646M 34.51% | -2.04M 90.97% | -2.04M 91.20% | -1.02M 94.73% | -1.02M 94.22% | -1.02M 50.00% | -1.02M 50.00% | -1.02M | -1.02M |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
IO BIOTECH INC / IOBT Forecast FAQ
Can you provide the upcoming earnings date for IO BIOTECH INC?
IO BIOTECH INC (IOBT) will report earnings on 2026-05-01.
What are the consensus estimates for IO BIOTECH INC (IOBT) next earnings?
The consensus EPS estimate for the next earnings of IO BIOTECH INC (IOBT) is -0.27 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for IO BIOTECH INC (IOBT) stock?
The consensus rating for IO BIOTECH INC (IOBT) is 50 / 100 . This indicates that analysts generally have a neutral outlook on the stock.